UNSPSC 51132212: Acetaminophen/caffeine/hyoscyamus

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132212 Acetaminophen/caffeine/hyoscyamus is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and over-the-counter medications sourced through government health and human services channels, though the specific combination named in the code title does not appear in the recent solicitations. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies. The work involves competitive procurement of generic pharmaceuticals, naloxone and drug deactivation systems, and OTC products for distribution to government facilities, health departments, and community health initiatives, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and established insurance and E-Verify requirements.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefit programs, with responses due April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026. MMCAP's evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers and comply with specific pricing formats and administrative fee structures.